Alpha 2.0
Login Register
» Articles » PMID: 29616611

Dominant Influenza A(H3N2) and B/Yamagata Virus Circulation in EU/EEA, 2016/17 and 2017/18 Seasons, Respectively

Overview
Journal Euro Surveill
Specialty Infectious Diseases
Date 2018 Apr 5
PMID 29616611
Citations 42
Authors
Cornelia Adlhoch
Rene Snacken
Angeliki Melidou
Silviu Ionescu
Pasi Penttinen
Affiliations
Soon will be listed here.
Abstract

We use surveillance data to describe influenza A and B virus circulation over two consecutive seasons with excess all-cause mortality in Europe, especially in people aged 60 years and older. Influenza A(H3N2) virus dominated in 2016/17 and B/Yamagata in 2017/18. The latter season was prolonged with positivity rates above 50% among sentinel detections for at least 12 weeks. With a current west-east geographical spread, high influenza activity might still be expected in eastern Europe.

Citing Articles

Clinical Manifestations and Outcomes in Adults Hospitalized With Respiratory Syncytial Virus and Influenza a/B: A Multicenter Observational Cohort Study.

Clausen C, Egeskov-Cavling A, Hayder N, Sejdic A, Roed C, Gitz Holler J Open Forum Infect Dis. 2024; 11(10):ofae513.

PMID: 39411215 PMC: 11474596. DOI: 10.1093/ofid/ofae513.

Prevalence of Influenza B/Yamagata Viruses From Season 2012/2013 to 2021/2022 in Italy as an Indication of a Potential Lineage Extinction.

Marchi S, Bruttini M, Milano G, Manini I, Chironna M, Pariani E Influenza Other Respir Viruses. 2024; 18(9):e13359.

PMID: 39257041 PMC: 11387461. DOI: 10.1111/irv.13359.

Molecular characterisation of influenza B virus from the 2017/18 season in primary models of the human lung reveals improved adaptation to the lower respiratory tract.

Caliskan D, Kumar S, Hinse S, Schughart K, Wiewrodt R, Fischer S Emerg Microbes Infect. 2024; 13(1):2402868.

PMID: 39248230 PMC: 11421153. DOI: 10.1080/22221751.2024.2402868.

-deficient MDCK cell based on CRISPR/Cas9 technology for enhancing influenza virus replication and improving vaccine production.

Mayuramart O, Poomipak W, Rattanaburi S, Khongnomnan K, Anuntakarun S, Saengchoowong S PeerJ. 2022; 10:e13989.

PMID: 36164603 PMC: 9508885. DOI: 10.7717/peerj.13989.

Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus.

Kang H, Chu K, Yoon K, Eom G, Mao J, Quan F Biomedicines. 2022; 10(7).

PMID: 35884922 PMC: 9313027. DOI: 10.3390/biomedicines10071618.

References
1.
Paget J, Marquet R, Meijer A, van der Velden K . Influenza activity in Europe during eight seasons (1999-2007): an evaluation of the indicators used to measure activity and an assessment of the timing, length and course of peak activity (spread) across Europe. BMC Infect Dis. 2007; 7:141. PMC: 2216029. DOI: 10.1186/1471-2334-7-141. View
2.
Meijer A, Brown C, Hungnes O, Schweiger B, Valette M, van der Werf S . Programme of the Community Network of Reference Laboratories for Human Influenza to improve Influenza Surveillance in Europe. Vaccine. 2006; 24(44-46):6717-23. DOI: 10.1016/j.vaccine.2006.05.068. View
3.
Vestergaard L, Nielsen J, Krause T, Espenhain L, Tersago K, Bustos Sierra N . Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. Euro Surveill. 2017; 22(14). PMC: 5388126. DOI: 10.2807/1560-7917.ES.2017.22.14.30506. View
4.
Karageorgopoulos D, Vouloumanou E, Korbila I, Kapaskelis A, Falagas M . Age distribution of cases of 2009 (H1N1) pandemic influenza in comparison with seasonal influenza. PLoS One. 2011; 6(7):e21690. PMC: 3128617. DOI: 10.1371/journal.pone.0021690. View
5.
Beaute J, Broberg E, Plata F, Bonmarin I, Donnell J, Delgado C . Overrepresentation of influenza A(H1N1)pdm09 virus among severe influenza cases in the 2011/12 season in four European countries. Euro Surveill. 2012; 17(9). View